India to Japan: Amlodipine Export Trade Route

To import Amlodipine formulations into Japan, the following approvals and registrations are necessary:

1. Marketing Authorization Holder (MAH): Foreign manufacturers must appoint a Japanese entity as their MAH or Designated Marketing Authorization Holder (DMAH) to manage the product registration and ensure compliance with local regulations.

2. Foreign Manufacturer Registration (FMR): Manufacturers outside Japan must obtain FMR from the Ministry of Health, Labour and Welfare (MHLW). This process, known as "Toroku," involves submitting detailed information about the manufacturing facility and its quality management systems.

3. Product Registration Application: The application should be compiled in the Common Technical Document (CTD) format, encompassing modules on administrative information, quality, non-clinical, and clinical data.

4. GMP Compliance Inspection: PMDA conducts Good Manufacturing Practice (GMP) inspections to verify that manufacturing sites comply with Japanese standards. These inspections can be document-based or on-site, depending on the product's risk classification.

Indian manufacturers exporting Amlodipine formulations to Japan must adhere to the following GMP standards:

1. GMP Certification: Manufacturing facilities must comply with Japanese GMP standards, which align with international guidelines. PMDA conducts inspections to ensure compliance.

2. Approved Facilities: As of December 2021, Sai Life Sciences' API manufacturing facility in Bidar, India, received a Certificate of Inspection from PMDA following a paper-based compliance inspection.

3. Recent Inspections: In August 2012, Inogent Laboratories in Hyderabad, India, successfully cleared a PMDA audit, indicating compliance with Japanese GMP standards.

In the past 18 months, several regulatory changes have impacted Indian pharmaceutical exports to Japan:

1. GMP Inspection Guidelines: In August 2025, PMDA updated its guidelines on documents required for GMP compliance inspections, emphasizing the need for comprehensive documentation from foreign manufacturers. (pmda.go.jp)

2. Quality Assurance Reports: In September 2025, PMDA published the GMP/GCTP Annual Report for FY 2024, detailing inspection activities and identified deficiencies, providing insights into common compliance issues. (pmda.go.jp)

These developments underscore the importance of maintaining rigorous quality standards and staying informed about regulatory updates to ensure successful market entry into Japan.

In 2024, Japan's pharmaceutical market was valued at approximately ¥10 trillion, with cardiovascular agents, including Amlodipine formulations, accounting for a significant portion due to the country's aging population and high prevalence of hypertension. The universal health coverage system ensures widespread access to these medications, driving consistent demand. While Japan maintains a robust domestic pharmaceutical manufacturing sector, it also imports a substantial volume of finished pharmaceutical formulations to meet its healthcare needs.

Japan's import duty for pharmaceutical products classified under HS code 30049072, which includes finished formulations containing Amlodipine, is set at 0% under the Most-Favored-Nation (MFN) status. Additionally, the Japan-India CEPA provides preferential tariff treatment for pharmaceutical imports from India, effectively maintaining the import duty at zero. Japan does not impose anti-dumping duties on these products. However, a consumption tax of 10% applies to all goods, including pharmaceuticals, upon importation.

India is a notable supplier of Amlodipine formulations to Japan, with exports totaling $14.5 million USD across 168 shipments. The primary Indian exporters include MEDREICH LIMITED and LUPIN LIMITED. The main Japanese importers are MEIJI SEIKA PHARMATECH CO., LTD and MEIJI SEIKA PHARMA CO., LTD. While India contributes significantly to Japan's Amlodipine imports, other major supplying countries include European nations, which collectively account for a substantial portion of Japan's pharmaceutical imports. India's competitive pricing, bolstered by the zero import duty under the Japan-India CEPA, positions it favorably against competitors from Europe and other regions.

India is a leading global supplier of generic pharmaceuticals, accounting for approximately 20% of the world's generic medicine supply by volume as of 2024. The country's pharmaceutical industry is valued at over $50 billion, with exports exceeding $25 billion in the fiscal year 2023–24.

The nation boasts a robust manufacturing infrastructure, with over 650 U.S. FDA-approved facilities operating within its borders. This extensive network enables large-scale production of finished dosage forms, including tablets, capsules, and syrups containing Amlodipine.

India's cost-effective production capabilities are bolstered by a skilled workforce and favorable regulatory environments. The country has also surpassed the United States in the number of FDA-registered generic manufacturing sites, with 752 FDA-approved, 2,050 WHO GMP-certified, and 286 EDQM-approved plants as of 2024.

India's Amlodipine formulations are competitively priced compared to those from China and the European Union. The country's pharmaceutical exports have been growing at 9%, nearly twice the global average, indicating strong demand and cost competitiveness.

In terms of quality, Indian manufacturers adhere to stringent international standards, with numerous facilities holding certifications from the U.S. FDA, WHO GMP, and EDQM. This compliance ensures that Indian Amlodipine formulations meet the quality expectations of regulated markets, including Japan.

Supply reliability is a hallmark of India's pharmaceutical industry, with the country supplying 40% of the U.S. generic drug market and 25% of all medicines in the UK. This track record underscores India's capability to meet international demand consistently.

India's pharmaceutical sector has demonstrated robust supply reliability, with exports increasing at 9%, nearly double the global average. The country has also surpassed the United States in the number of FDA-registered generic manufacturing sites, with 752 FDA-approved, 2,050 WHO GMP-certified, and 286 EDQM-approved plants as of 2024.

Packaging and cold chain capabilities are well-established, ensuring the integrity of finished dosage forms during transit. There have been no significant supply disruptions reported in recent years, reflecting the industry's resilience.

Leading Indian manufacturers continue to expand their capacities to meet growing global demand. For instance, the generic injectable market in India was valued at $3.0 billion in 2024 and is projected to grow at a CAGR of 10.28%, reaching $7.6 billion by 2033.

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply chain disruptions.

• Negotiate Favorable Payment Terms: Standard payment terms in India-Japan pharmaceutical trade often include letters of credit or advance payments; negotiate terms that align with your financial strategies.

• Establish Minimum Order Quantities (MOQs): Discuss and agree upon MOQs with suppliers to ensure cost-effective procurement without overstocking.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on regulatory compliance, production capacity, quality assurance practices, and past performance in international markets.

• Monitor Regulatory Compliance: Regularly review suppliers' adherence to international standards and certifications to ensure consistent product quality and compliance with Japanese regulatory requirements.

1. Regulatory Compliance Verification: Confirm that the Indian supplier's Amlodipine formulations are registered with Japan's Pharmaceuticals and Medical Devices Agency (PMDA). Ensure the supplier holds a valid Good Manufacturing Practice (GMP) certificate recognized by PMDA.

2. Drug Master File (DMF) Assessment: Obtain and review the supplier's DMF for Amlodipine formulations to verify comprehensive product information, including manufacturing processes, quality controls, and stability data.

3. Quality Management System Evaluation: Assess the supplier's quality management system to ensure it aligns with international standards such as ISO 9001.

4. Certifications Review: Verify the supplier's compliance with WHO-GMP standards and confirm the validity of their GMP certificate issued by India's Central Drugs Standard Control Organization (CDSCO).

5. Regulatory History Check: Investigate the supplier's history for any regulatory actions, such as FDA warning letters or WHO-GMP suspensions, which may indicate compliance issues.

6. Export Experience Confirmation: Confirm the supplier's track record of exporting Amlodipine formulations to Japan or other Asia-Pacific markets, indicating familiarity with regional regulatory requirements.

7. Pricing Analysis: Evaluate the supplier's pricing to ensure it aligns with market standards, avoiding unusually low prices that may suggest quality compromises.

8. Audit Readiness Assessment: Ensure the supplier is open to and prepared for factory audits, demonstrating transparency and commitment to quality.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming the product meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for regulatory compliance and tariff considerations.

3. Good Manufacturing Practice (GMP) Certificate: Issued by CDSCO, this certificate confirms the manufacturing facility complies with GMP standards, ensuring product quality and safety.

4. Stability Data: Includes studies conducted under International Council for Harmonisation (ICH) guidelines to demonstrate the product's shelf life and stability under various conditions.

5. Batch Manufacturing Records: Detailed documentation of the production process for each batch, ensuring traceability and consistency in manufacturing.

6. Drug Master File (DMF): Comprehensive document detailing the manufacturing process, controls, and specifications of the Amlodipine formulation, facilitating regulatory review.

7. Free Sale Certificate: Issued by CDSCO, this certificate indicates that the product is approved for sale in India, suggesting compliance with local regulations.

8. Insurance Certificates: Proof of liability insurance coverage, providing assurance of financial responsibility in case of product-related issues.

1. Regulatory Non-Compliance: Recent FDA warning letters or WHO-GMP certificate suspensions may indicate serious compliance issues.

2. Unrealistically Low Pricing: Prices significantly below market rates may suggest potential compromises in product quality or manufacturing standards.

3. Lack of Stability Data: Inability to provide comprehensive stability data raises concerns about the product's shelf life and efficacy.

4. Limited Export Experience: No history of exporting Amlodipine formulations to Japan or other Asia-Pacific markets may indicate unfamiliarity with regional regulatory requirements.

5. Resistance to Audits: Hesitation or refusal to allow factory audits suggests potential transparency issues or non-compliance with quality standards.

1. Pre-Audit Desktop Review: Conduct a thorough review of the supplier's documentation, including quality manuals, SOPs, and previous audit reports, to identify potential areas of concern.

3. Post-Audit Corrective Actions: Require the supplier to address any identified deficiencies within a specified timeframe, providing evidence of corrective actions taken.

4. Annual Re-Qualification Process: Implement a yearly review of the supplier's compliance and performance, including updated audits and documentation reviews.

5. Remote Monitoring Options: Utilize virtual audits, regular video conferences, and electronic document reviews to maintain oversight between on-site audits.